Edition:
United Kingdom

Adocia SA (ADOC.PA)

ADOC.PA on Paris Stock Exchange

11.68EUR
19 Sep 2019
Change (% chg)

€0.18 (+1.57%)
Prev Close
€11.50
Open
€11.56
Day's High
€11.68
Day's Low
€11.54
Volume
391
Avg. Vol
33,251
52-wk High
€22.60
52-wk Low
€10.06

Summary

Name Age Since Current Position

Gerard Soula

74 2011 Chairman of the Board, Chief Executive Officer

Olivier Soula

48 2012 Deputy Chief Executive Officer, Vice President - Research & Development, Director

Valerie Danaguezian

Chief Financial Officer, Administrative Director

You-Ping Chan

Scientific Director

Remi Soula

Business Development and Intellectual Property Director

Geraldine Soula

Director of Development and Human Resources

Bertrand Alluis

Head of Analysis Department and Project Manager

Richard Charvet

Head of Chemistry Department

Jose Correia

Head of the Preclinical and Clinical Department, HSQE Manager and Project Manager

David Duracher

Head of Pharmaceutical Development and Physical Chemistry Departments

Martin Gaudier

Head of Biology Department

Stanislav Glezer

Medical Doctor

Sarah Gould

Director of the Preclinical Department

Gregory Meiffren

Head of Biology Department

Laurent Arthaud

55 2011 Director Representative of Bpifrance Investissement

Olivier Martinez

Director

Ekaterina Smirnyagina

53 2013 Independent Director

Dominique Takizawa

61 2011 Independent Director

Biographies

Name Description

Gerard Soula

Dr. Gerard Soula has served as Chairman of the Board, Chief Executive Officer at Adocia SA since October 24, 2011. He founded Flamel Technologies, a biotech Company based in Lyon for which he was the CEO for 15 years. Dr. Soula was previously Director of Scientific Research at Rhone Poulenc and obtained the Rhone Poulenc Prize in innovation for his invention of a new type of catalyst, based on molecular self-assembly. More recently, he received the Chaptal Prize for his contributions in the development of pharmaceutical innovations. He is the co-author of 123 patents. He holds doctorate in organic chemistry and is graduate of IAE.

Olivier Soula

Dr. Olivier Soula has served as Vice President - Research & Development Deputy Chief Executive Officer and Member of the Board of Directors at Adocia SA since December 19. 2012. He is graduate of ENSIC and he holds a Ph.D. in polymer science and an MBA from IAE, Lyon. He worked for eight years at Flamel Technologies as Director of the Nanotechnologies department. He was in charge of a team dedicated to the innovation of protein delivery systems, in partnerships with pharmaceutical companies. He was also responsible for the development and the implementation of the IT System. He is co-author of 31 patents relating to protein delivery.

Valerie Danaguezian

Ms. Valerie Danaguezian is Chief Financial Officer and Administrative Director at Adocia SAS. She worked for four years as an external auditor at Cala Ramolino & Associes (Deloitte & Touche). In 1991, she joined Sanofi Pasteur where she was in charge of the financial consolidation of the group; she was thento Director of Research & Development controlling. In 2003 she joined Flamel Technologies as Financial Director, a position she held for three years. She joined Adocia at its inception as Financial Director and member of Adocia Committe management.

You-Ping Chan

Mr. You-Ping Chan is Scientific Director at Adocia SA. He holds a doctorate in chemistry from the University of Strasbourg. He completed a post-doctorate at MIT and an MBA at EMLyon. He worked at Flamel Technologies for twenty years, holding several management positions in research, in the development of biodegradable polymers and protein formulations. He has co-authored ten scientific publications and is a co-holder of 40 patents. He is in charge of CMC scientific activities.

Remi Soula

Dr. Remi Soula is Business Development and Intellectual Property Director at Adocia SAS. He holds a doctorate in polymer chemistry from CPE Lyon. He did a post-doctorate at Max-Planck Institute in Berlin. He began his career with Flamel Technologies as a senior researcher where, over the course of three years, he acquired solid experience in the synthesis of new polymers. He is a co-holder of 30 patents and has co-authored six scientific publications.

Geraldine Soula

Ms. Geraldine Favre Soula is Director of Development and Human Resources at Adocia SA. She began her career with Bouygues as Head of Vocational Training, and then continued at Pasteur Merieux (Sanofi Pasteur) and in Alptis by occupying management positions Generalist HR function. She was then Head of Human Resources Development at Flamel Technologies for nine years, during which the number rose from 50 to 300 people and where she developed a department and HR team on two sites (Lyon and Bordeaux). She works at Adocia since its creation.

Bertrand Alluis

Dr. Bertrand Alluis is Head of Analysis Department and Project Manager of Adocia SAS. He holds a doctorate in chemistry. He did his dissertation at the CNRS polyphenols laboratory at the University of Lyon I, and studied the complex and antioxidant powers of flavonoids. He spent three years with Diatos S.A. in the field of oncology and vectorization as head of the therapeutic chemistry department. Thereafter, he joined Flamel Technologies where, for three years as senior researcher, he specialized in the development and validation of analytical methods used to characterize proteins and the formulation thereof with polymers. He is a co-holder of three patents and has co-authored four scientific publications.

Richard Charvet

Dr. Richard Charvet is Head of Chemistry Department at Adocia SAS. He earned a doctorate in organic chemistry and polymers from North Carolina State University, Raleigh, in the United States. He did a two-and-a-half year post-doctorate at Erato Nanospace Project in Tokyo, and then spent one year at the University of Wuppertal. Thereafter, he joined the National Institute for Materials Science (NIMS) in Tsukuba, Japan, as an associate researcher studying organic photoconductive nanostructures formed by supramolecular self-assembly. He is a co-holder of 21 patents and has co-authored 18 scientific publications.

Jose Correia

Dr. Jose Correia is Head of the Preclinical and Clinical Department, HSQE Manager and Project Manager at Adocia SAS. He holds a doctorate in biomaterials engineering from the University of Paris-Nord. He was chairman and chief executive officer of Biodex from 2002 to 2006, where he managed chemical and pharmaceutical development for nine years. He is a co-holder of four patents and has co-authored three scientific publications.

David Duracher

Dr. David Duracher is Head of Pharmaceutical Development and Physical Chemistry Departments at Adocia SAS. He holds a doctorate in polymer physical chemistry. His dissertation, which was financed by BioMerieux, was in the field of biomedical diagnostics, at the interface between the science of polymers and biology. After a post-doctorate at the Key Centre for Polymer Colloids at the University of Sydney and two years’ experience in the field of biochips with Apibio, he worked for Flamel Technologies on sustained release formulations for therapeutic proteins. He is a co-holder of six patents and has co-authored eighteen publications.

Martin Gaudier

Dr. Martin Gaudier is Head of Biology Department at Adocia SAS. He holds an engineering degree from Ecole Polytechnique and a doctorate in structural biology and protein biochemistry. He did his dissertation in the field of structural virology, and then a four-year post-doctorate at Cancer Research UK in London on protein-DNA interactions. He has co-authored eight scientific publications and is a co-holder of two patents.

Stanislav Glezer

Mr. Stanislav Glezer is Medical Director at Adocia SA. He is a medical doctor with a degree from the the Moscow State University of Medicine and Stomatology. He has also earned a clinical research degree from McGill University, and an MBA from California Coast University. Before joining Adocia he served as Vice President, Medical Affairs for Novo Nordisk. He previously held management positions at Sanofi, including Global Leader of the Toujeo® project, Vice President Evidence Value and Access and Vice President Medical Affairs.

Sarah Gould

Ms. Sarah Gould serves as Director of the Preclinical Department. She holds a doctorate in biology and toxicology. She has worked in the pharmaceutical industry for more than 20 years, at Astrazeneca, Sanofi Pasteur. She has also served as a toxicology and pharmacology consultant for Merck, Pfizer, and GSK, where she managed regulatory applications in liaison with the relevant authorities (FDA, EMA and PMDA). She is co-author of 20 scientific publications.

Gregory Meiffren

Dr. Gregory Meiffren is HEad of Biology Department of Adocia SA. He is a graduate of the Ecole Normale Supérieure, Lyon and Doctor of Cellular Biology. He carried out his thesis on the transduction pathways of immune cells in various pathologies at the Centre d’Etudes et de Recherches en Virologie et Immunologie in Lyon and also collaborated with the Dana-Farber Cancer Institute and the Brigham and Women’s Hospital in Boston. He is a co-holder of one patent and has co-authored six scientific publications.

Laurent Arthaud

Mr. Laurent Arthaud has served as Director Representative of Bpifrance Investissement on the Board of Directors at Adocia SA since October 24, 2011. He is also Chairman of the Remuneration Committee of the Company. He started his carrier in 1986 at INSEE and then joined the French Ministry of Finances and Economy. In 1993, he was advisor of the French Ministry of Labour and created the "Cheque Emploi Service". In 1997, he joined Rhone Poulenc as General Secretary of the group's Scientific Division, where in particular he was in charge of external collaborations. In 1999, he created Aventis Capital, a capital investment subsidiary of Aventis in partnership with Societe Generale. In 2004, he became Chief Executive Officer (CEO) of Pharmavent Partners, a new capital investment fund. He joined CDC Entreprises in 2006, as Director in charge of new developments. In 2009, he became Deputy CEO at CDC Entreprises, Manager of InnoBio fund. Mr. Arthaud is a graduate of Ecole Polytechnique and Ecole Nationale de Statistique et d'Administration Economique.

Olivier Martinez

Dr. Olivier Martinez serves as a Member of the Board of Directors at Adocia SA. He is Member of company's Audit Committee. From 1992 to 1997, he pursued his doctoral studies in cell biology at the Pasteur and Curie Institutes in Paris. After undergoing management training, he joined the Life Science Group of Gemini Consulting and spent two years working on healthcare projects. In 2000 he joined Bioam Gestion as an Associate and became Investment Manager and member of the executive board in 2004. Following the integration of Bioam Gestion into CDC Entreprises in July 2010, he is now in charge of managing investments of the InnoBio and Bioam funds. Dr. Martinez is a graduate of the Ecole Normale Superieure (Ulm) and holds a Ph.D. in cell biology from the University of Paris XI and a diploma from the College des Ingenieurs.

Ekaterina Smirnyagina

Ms. Ekaterina Smirnyagina has been Independent Director of Adocia SA since June 18, 2013. She is Member of the Remuneration Committee. After completing her Ph.D. in Microbiology & Immunology at the Stanford School of Medicine, she began her career in the Consulting and Development Business of Biotechnology. She then worked at Alta Partners, an investment fund company specializing in health care in San Francisco from 2002 to 2012. Since then, she has been a director of the Capricorn Venture Partners investment fund in Belgium.

Dominique Takizawa

Ms. Dominique Takizawa has served as an Independent Member of the Board of Directors at Adocia SAS since October 24, 2011. She is Chairwoman of the Audit Committee. Ms. Takizawa has filled various roles in the group, both at the ACCRA (now Merieux Alliance) and bioMerieux levels: she assisted Alain Merieux and the management team in the group's strategic development, specifically during merger and acquisition transactions, alongside other shareholders and investors, and in market transactions. She had formerly filled the role of Financial Director and Controller for Institut Merieux, Merial and Aventis CropScience, in particular during strategic changes. She is a Member of the Board of Merieux Nutrisciences, Avesthagen and April Group. She chaired the Board of Directors of Transgene as the permanent representative of the NBMA, then TSGH, from 2002 to 2004. She is a graduate of the Ecole des Hautes Etudes Commerciales and has a chartered accountant's diploma.